Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy

This study aimed to evaluate the major changes of the eighth edition of the American Joint Committee on Cancer (AJCC) pathologic staging for prostate cancer treated with radical prostatectomy. A total of 138,176 patients diagnosed with prostate adenocarcinoma undergoing radical prostatectomy were se...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-11, Vol.12 (11), p.e0187887-e0187887
Main Authors: Xiao, Wen-Jun, Zhu, Yao, Dai, Bo, Ye, Ding-Wei
Format: Article
Language:English
Subjects:
Adenocarcinoma
Biology and Life Sciences
Cancer
Cancer surgery
Care and treatment
Committees
Diagnosis
Disease-Free Survival
Epidemiology
Humans
Kallikreins - metabolism
Male
Median (statistics)
Medical diagnosis
Medical prognosis
Medicine and Health Sciences
Methods
Middle Aged
Neoplasm Grading
Neoplasm Staging
Oncology
Pathology
Practice guidelines (Medicine)
Practice Guidelines as Topic
Prognosis
Prostate cancer
Prostate-Specific Antigen - metabolism
Prostatectomy
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Quality
SEER Program
Studies
Subgroups
Surveillance
Survival
Survival Analysis
Treatment Outcome
Tumors
United States
Urological surgery
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to evaluate the major changes of the eighth edition of the American Joint Committee on Cancer (AJCC) pathologic staging for prostate cancer treated with radical prostatectomy. A total of 138,176 patients diagnosed with prostate adenocarcinoma undergoing radical prostatectomy were selected from the Surveillance, Epidemiology and End Results (SEER) database during 2004-2014 period. Excluded were cases with incomplete or unavailable staging, PSA and Gleason score information. Two subgroups were established: group a, T2 stage with PSA≥20ng/ml; group b, T2 stage with Gleason score grade group 5 and PSA
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0187887